SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Sees Large Decrease in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,700 shares, a decrease of 60.5% from the November 30th total of 4,300 shares. Based on an average daily volume of 16,200 shares, the short-interest ratio is currently 0.1 days.

SAB Biotherapeutics Trading Down 11.1 %

SABSW opened at $0.08 on Friday. SAB Biotherapeutics has a 12-month low of $0.01 and a 12-month high of $0.19. The stock has a fifty day simple moving average of $0.06 and a two-hundred day simple moving average of $0.05.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.